Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Associations Between ADHD Medication Use in Pregnancy and Severe Malformations Based on Prenatal and Postnatal Diagnoses: A Danish Registry-Based Study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Antidepressant use in pregnancy and severe cardiac malformations: Danish register-based study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Crown-rump length measurement error: impact on assessment of growth

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Kongenitte portosystemiske shunter, diagnose og behandling af en multisystemisk sygdom hos børn

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. National data on the early clinical use of non-invasive prenatal testing in public and private healthcare in Denmark 2013-2017

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Genetisk screening af kommende forældre

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  • Line Kolding
  • Vera Ehrenstein
  • Lars Pedersen
  • Puk Sandager
  • Olav B Petersen
  • Niels Uldbjerg
  • Lars H Pedersen
Vis graf over relationer

OBJECTIVE: Attention-deficit/hyperactivity disorder (ADHD) medications are increasingly used in pregnancy. Studies on the pregnancy safety of these medications that are restricted to live births may underestimate severe teratogenic effects that cause fetal demise or termination of pregnancy. The present study addresses this limitation by including data from both prenatal and postnatal diagnoses of major malformations.

METHODS: A nationwide registry-based study was conducted of 364,012 singleton pregnancies in Denmark from November 1, 2007, to February 1, 2014. Exposures to ADHD medication were obtained from redeemed prescriptions from the Danish Health Services Prescription Database. Outcome data included prenatally diagnosed malformations from the Danish Fetal Medicine Database and postnatally diagnosed malformations from the Danish National Patient Registry. The primary outcome was major malformations overall, and secondary outcomes were malformations of the central nervous system and cardiac malformations. The comparison group was pregnancies with no redeemed prescriptions for ADHD medication. We defined severe cardiac malformations (SCM) as concurrent diagnoses of a cardiac malformation with miscarriage, termination, stillbirth, postnatal death, or cardiac surgery within 1 year of birth.

RESULTS: The prevalence of first-trimester exposure to ADHD medication increased during the study period from 0.05% in 2008 to 0.27% in 2013, with the majority (473/569) of the exposures being to methylphenidate. There were 5.1% malformations overall and 2.1% cardiac malformations among the exposed compared to 4.6% and 1.0%, respectively, among the unexposed. For methylphenidate, the adjusted prevalence ratios (PRs) were 1.04 (95% confidence interval [CI], 0.70-1.55) for malformations overall and 1.65 (95% CI, 0.89-3.05) for any cardiac malformations (number needed to harm [NNH] = 92), with septum defects in 10 out of 12 cases. The PR for ventricular septal defect was 2.74 (95% CI, 1.03-7.28) and for SCM, 2.59 (95% CI, 0.98-6.90).

CONCLUSIONS: Exposure to methylphenidate was not associated with an increased risk of malformations overall in data that included information from both prenatal and postnatal diagnoses of major malformations. There was an increased risk of cardiac malformations with NNH of 92 based on 12 cases among the exposed. More data are needed on other types of ADHD medication.

OriginalsprogEngelsk
TidsskriftThe Journal of Clinical Psychiatry
Vol/bind82
Udgave nummer1
Sider (fra-til)20m13458
ISSN0160-6689
DOI
StatusUdgivet - 5 jan. 2021

Bibliografisk note

© Copyright 2021 Physicians Postgraduate Press, Inc.

ID: 61709406